Brain scans reveal how experimental drug affects memory in schizophrenia

NCT ID NCT04457310

First seen Nov 01, 2025 · Last updated Jun 12, 2026 · Updated 37 times

Summary

This study tested an experimental drug called CVL-562 in 112 people with early schizophrenia to see how it affects brain activity during memory tasks. Participants had five brain scans (fMRI) while doing a spatial memory exercise. The goal was to find brain markers that could help develop better treatments for memory and thinking problems in schizophrenia.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EARLY COURSE SCHIZOPHRENIA SPECTRUM DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Columbia University

    New York, New York, 10032, United States

  • Stony Brook University

    Stony Brook, New York, 11794, United States

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

  • Yale University

    New Haven, Connecticut, 06511, United States

Conditions

Explore the condition pages connected to this study.

Conditions inferred from the trial description

These were inferred from the trial's summary, not listed by the trial registrant.